NASDAQ · MNKD
Healthcare · Biotechnology
$3.71
Down-$0.11 (-2.88%)
Updated Oct 7, 2026, 5:02 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MNKD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MNKD closed at $3.71 after 21 trading sessions, down 10.82% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $3.86 | $3.86 | $3.69 | $3.71 | 3.07M |
| Oct 5, 2026 | $3.82 | $3.85 | $3.70 | $3.82 | 2.88M |
| Oct 2, 2026 | $4.01 | $4.01 | $3.705 | $3.80 | 4.61M |
| Oct 1, 2026 | $3.84 | $4.225 | $3.83 | $3.95 | 10.19M |
| Sep 30, 2026 | $3.37 | $4.03 | $3.30 | $3.90 | 15.02M |
| Sep 29, 2026 | $3.35 | $3.375 | $3.28 | $3.34 | 2.38M |
| Sep 28, 2026 | $3.34 | $3.38 | $3.275 | $3.35 | 2.08M |
| Sep 25, 2026 | $3.32 | $3.39 | $3.17 | $3.34 | 8.85M |
| Sep 24, 2026 | $3.33 | $3.33 | $3.23 | $3.29 | 2.96M |
| Sep 23, 2026 | $3.48 | $3.48 | $3.34 | $3.34 | 2.88M |
| Sep 22, 2026 | $3.53 | $3.55 | $3.255 | $3.49 | 16.3M |
| Sep 21, 2026 | $3.55 | $3.62 | $3.47 | $3.50 | 4.53M |
| Sep 18, 2026 | $3.59 | $3.6207 | $3.50 | $3.54 | 5.51M |
| Sep 17, 2026 | $3.61 | $3.68 | $3.53 | $3.58 | 2.73M |
| Sep 16, 2026 | $3.57 | $3.61 | $3.52 | $3.55 | 2.23M |
| Sep 15, 2026 | $3.74 | $3.75 | $3.535 | $3.56 | 3.7M |
| Sep 14, 2026 | $3.76 | $3.84 | $3.73 | $3.75 | 3.13M |
| Sep 11, 2026 | $3.83 | $3.85 | $3.73 | $3.75 | 2.47M |
| Sep 10, 2026 | $3.90 | $3.90 | $3.76 | $3.79 | 3.21M |
| Sep 9, 2026 | $4.155 | $4.36 | $3.92 | $3.94 | 5.19M |
| Sep 8, 2026 | $4.00 | $4.32 | $4.00 | $4.16 | 4.93M |
The latest Smart Investors Daily articles mentioning MNKD.
Company
Market Activity
Research & News
MNKD research
Company profile and research snapshot.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| May 7, 2026 | Wells Fargo | Overweight | — |
| May 7, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 27, 2026
United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock is a Buy now.
Yahoo · Sep 17, 2026
MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase
Yahoo · Sep 16, 2026
On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. The deal hands MannKind an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, without saddling it with the […]
Benzinga · Sep 11, 2026
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MNKD.
